title: Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors.
abstract: Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Sonazoid-enhanced ultrasound and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI are the most important imaging modalities in diagnosing HCC. There are 2 non-contradictory HCC treatment algorithms in Japan. Hepatic arterial infusion chemotherapy plays an important role in the treatment of advanced HCC with main or branch portal vein invasion. Regorafenib, as a second-line systemic treatment, prolongs survival in patients with intermediate and advanced HCC who progressed on sorafenib. In recent clinical trials, immune check point inhibitors show promising results for the treatment of HCC. This review describes recent trends in the management of HCC.
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
mesh_terms: D000906:Antibodies / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000276:immunology; D005290:Ferric Compounds; D019786:Gadolinium DTPA; D006801:Humans; D007501:Iron; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008279:Magnetic Resonance Imaging / Q000379:methods; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D010087:Oxides; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000077157:Sorafenib; D014463:Ultrasonography / Q000379:methods
chemical_list: D000906:Antibodies; D000970:Antineoplastic Agents; D005290:Ferric Compounds; D010087:Oxides; C105992:PDCD1 protein, human; D010671:Phenylurea Compounds; D061026:Programmed Cell Death 1 Receptor; D011725:Pyridines; C069727:Sonazoid; C073590:gadolinium ethoxybenzyl DTPA; C559147:regorafenib; D009536:Niacinamide; D000077157:Sorafenib; D007501:Iron; D019786:Gadolinium DTPA